Bridge Biotherapeutics Current Ratio vs. Market Capitalization
| 288330 Stock | KRW 4,050 445.00 9.90% |
For Bridge Biotherapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bridge Biotherapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bridge Biotherapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bridge Biotherapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bridge Biotherapeutics over time as well as its relative position and ranking within its peers.
Bridge |
Bridge Biotherapeutics Market Capitalization vs. Current Ratio Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Bridge Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Bridge Biotherapeutics value to that of its competitors to determine the firm's financial worth. Bridge Biotherapeutics is rated below average in current ratio category among its peers. It is rated third in market capitalization category among its peers creating about 206,733,333,333 of Market Capitalization per Current Ratio. Comparative valuation analysis is a catch-all model that can be used if you cannot value Bridge Biotherapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bridge Biotherapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Bridge Market Capitalization vs. Current Ratio
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Bridge Biotherapeutics |
| = | 1.05 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Bridge Biotherapeutics |
| = | 217.07 B |
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
Bridge Market Capitalization vs Competition
Bridge Biotherapeutics is rated third in market capitalization category among its peers. Market capitalization of Biotechnology & Medical Research industry is presently estimated at about 1.03 Trillion. Bridge Biotherapeutics totals roughly 217.07 Billion in market capitalization claiming about 21% of stocks in Biotechnology & Medical Research industry.
Bridge Biotherapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Bridge Biotherapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bridge Biotherapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Bridge Biotherapeutics' change in net profit over the period of time. It can combine multiple indicators of Bridge Biotherapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. The company was founded in 2015 and is headquartered in Seongnam, Korea. BRIDGE BIOTHERAPEUTICS is traded on Korean Securities Dealers Automated Quotations in South Korea.
Bridge Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Bridge Biotherapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bridge Biotherapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bridge Biotherapeutics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Bridge Biotherapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Ceiling Movement Now
Price Ceiling MovementCalculate and plot Price Ceiling Movement for different equity instruments |
| All Next | Launch Module |
Use Investing Themes to Complement your Bridge Biotherapeutics position
In addition to having Bridge Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Transportation Thematic Idea Now
Transportation
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Transportation theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Transportation Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Bridge Stock
To fully project Bridge Biotherapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Bridge Biotherapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Bridge Biotherapeutics' income statement, its balance sheet, and the statement of cash flows.